These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 8986034

  • 21. [Efficacy of combined use of ursodeoxycholic acid and heptral in the treatment of primary biliary cirrhosis].
    Avezov SA, Mansurova FKh.
    Klin Med (Mosk); 2004; 82(2):46-9. PubMed ID: 15106512
    [Abstract] [Full Text] [Related]

  • 22. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
    Bonnand AM, Heathcote EJ, Lindor KD, Poupon RE.
    Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
    [Abstract] [Full Text] [Related]

  • 23. Long-term response of primary biliary cirrhosis (stage I) to therapy with ursodeoxycholic acid.
    Tromm A, May B, Klein CG, Klein R, Fisseler-Eckhoff A, Griga T.
    Hepatogastroenterology; 2005 Jan; 52(63):753-6. PubMed ID: 15966198
    [Abstract] [Full Text] [Related]

  • 24. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [Abstract] [Full Text] [Related]

  • 25. [The treatment of primary biliary liver cirrhosis with ursodeoxycholic acid (preliminary report)].
    Kolarski V.
    Vutr Boles; 1991 Sep; 30(1):65-70. PubMed ID: 1771866
    [Abstract] [Full Text] [Related]

  • 26. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
    Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD.
    Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
    [Abstract] [Full Text] [Related]

  • 27. [Methotrexate in the therapy of primary biliary cirrhosis].
    Weber P, Scheurlen M, Wiedmann KH.
    Dtsch Med Wochenschr; 1991 Sep 06; 116(36):1347-52. PubMed ID: 1884674
    [Abstract] [Full Text] [Related]

  • 28. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
    Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD.
    Hepatology; 1999 Mar 06; 29(3):644-7. PubMed ID: 10051462
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Cholestatic liver diseases--diagnosis and therapy. 3: Therapy of primary biliary cirrhosis].
    Leuschner U.
    Fortschr Med; 1998 Jan 20; 116(1-2):37-9. PubMed ID: 9522537
    [No Abstract] [Full Text] [Related]

  • 31. Long-term follow-up of patients with primary biliary cirrhosis on colchicine therapy.
    Zifroni A, Schaffner F.
    Hepatology; 1991 Dec 20; 14(6):990-3. PubMed ID: 1959887
    [Abstract] [Full Text] [Related]

  • 32. Methotrexate therapy in primary biliary cirrhosis.
    Sordá J, Findor J.
    Acta Gastroenterol Latinoam; 2000 Dec 20; 30(4):221-5. PubMed ID: 11086511
    [Abstract] [Full Text] [Related]

  • 33. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group.
    van Hoogstraten HJ, Vleggaar FP, Boland GJ, van Steenbergen W, Griffioen P, Hop WC, van Hattum J, van Berge Henegouwen GP, Schalm SW, van Buuren HR.
    Am J Gastroenterol; 2000 Aug 20; 95(8):2015-22. PubMed ID: 10950051
    [Abstract] [Full Text] [Related]

  • 34. Autoimmune conditions associated with primary biliary cirrhosis: response to ursodeoxycholic acid therapy.
    Zukowski TH, Jorgensen RA, Dickson ER, Lindor KD.
    Am J Gastroenterol; 1998 Jun 20; 93(6):958-61. PubMed ID: 9647028
    [Abstract] [Full Text] [Related]

  • 35. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
    Corpechot C, Poujol-Robert A, Wendum D, Galotte M, Chrétien Y, Poupon RE, Poupon R.
    Liver Int; 2004 Jun 20; 24(3):187-93. PubMed ID: 15189267
    [Abstract] [Full Text] [Related]

  • 36. [Clinical-dispensary finding of patients with primary biliary cirrhosis].
    Chernev K, Bakalov V.
    Vutr Boles; 1985 Jun 20; 24(4):42-6. PubMed ID: 2933878
    [Abstract] [Full Text] [Related]

  • 37. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.
    Heathcote EJ, Stone J, Cauch-Dudek K, Poupon R, Chazouilleres O, Lindor KD, Petz J, Dickson ER, Poupon RE.
    Liver Transpl Surg; 1999 Jul 20; 5(4):269-74. PubMed ID: 10388499
    [Abstract] [Full Text] [Related]

  • 38. Results of long-term ursodiol treatment for patients with primary biliary cirrhosis.
    Jorgensen R, Angulo P, Dickson ER, Lindor KD.
    Am J Gastroenterol; 2002 Oct 20; 97(10):2647-50. PubMed ID: 12385454
    [Abstract] [Full Text] [Related]

  • 39. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
    Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF.
    Am J Gastroenterol; 2006 Jul 20; 101(7):1529-38. PubMed ID: 16863557
    [Abstract] [Full Text] [Related]

  • 40. A pilot study on the hemodynamic effect of short-term ursodeoxycholic acid therapy in patients with stable liver cirrhosis.
    Baruch Y, Assy N, Weisbruch F, Reisner SA, Rinkevich D, Enat R, Blendis LM, Bomzon A.
    Am J Gastroenterol; 1999 Oct 20; 94(10):3000-4. PubMed ID: 10520859
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.